Starpharma Holdings Limited SPHRY
Set alert
3.25 USD -0.25 -7.14%
At close · Oct 30
3.02 Day range 3.25
2.10 52-week range 5.98
- YTD
- +33.74%
- 1 year
- +43.17%
- Open
- 3.02
- Prev close
- 3.50
- Mkt cap
- 156.95M
- Vol
- 1.10K
- Avg vol
- 945
- EPS
- -0.12
- P/E
- 0.00
More statistics
- Low
- 3.02
- High
- 3.25
3M chart
Events in this range
- Aug 10, 2026Dividend: 0.084
Signals (32)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 12, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| SMA: Bullish | Sep 25, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bullish | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 21, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
News
- Starpharma (OTCMKTS:SPHRY) Stock Price Down 13.7% – Time to Sell?
- US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments
- Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma
- Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack
- Starpharma Up With News, Down With None; Timing Entry Makes Sense
- Starpharma signs DEP® ADC Research Agreement with MSD
- Starpharma Viraleze: COVID-19 Nasal Spray Development
- Stocks That Hit 52-Week Lows On Tuesday
Your note
Sign in to keep a note on SPHRY — it syncs with the Stock Master app.